Patents by Inventor Stanley L. Hazen

Stanley L. Hazen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7491504
    Abstract: A method of detecting ovarian cancer in a female test subject comprising determining the amount of plasmenyl-PA or a biomarker having a mass charge ratio of approximately 655.3 in a sample of a bodily fluid taken from the female test subject and comparing the amount of plasmenyl-PA (or the biomarker) in the sample of the bodily fluid taken from the female test subject to a range of amounts of plasmenyl-PA (or the biomarker) found in samples of bodily fluids taken from a group of normal female subjects of the same species as the female test subject and lacking ovarian cancer, whereby a lower amount of the plasmenyl-PA (or the biomarker) in the sample of the bodily fluid taken from the female test subject indicates the presence of ovarian cancer.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: February 17, 2009
    Assignees: Frantz Biomarkers, LLC, The Cleveland Clinic Foundation
    Inventors: Lian Shan, Stanley L. Hazen
  • Publication number: 20090035874
    Abstract: The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD.
    Type: Application
    Filed: May 23, 2008
    Publication date: February 5, 2009
    Applicant: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Stanley L. Hazen, Marc S. Penn
  • Patent number: 7459286
    Abstract: Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: December 2, 2008
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Marc S. Penn, Renliang Zhang
  • Patent number: 7378396
    Abstract: The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: May 27, 2008
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Marc S. Penn
  • Publication number: 20040028749
    Abstract: The invention provides methods and materials related to the treatment of inflammation. Such inflammations include, without limitation, those inflammations mediated by eosinophils and/or neutrophils as well as those inflammations associated with peroxidase activity. The invention also provides methods and materials related to the treatment of complications associated with eosinophil-mediated inflammations and/or neutrophil-mediated inflammations. Specifically, the invention involves increasing the amount of pseudohalides in a mammal exhibiting inflammation and/or an associated condition.
    Type: Application
    Filed: May 1, 2003
    Publication date: February 12, 2004
    Inventors: Arne Slungaard, Stanley L. Hazen, Husam M. Abu-Soud
  • Publication number: 20030180218
    Abstract: A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of therapeutic agents comprises determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at base line or following administration of the therapeutic agent. The marker includes at least one of MPO activity, MPO mass, select MPO-generated oxidation products, and combinations thereof. The level of the systemic marker is compared with a predetermined value to monitor the anti-inflammatory and/or antioxidant actions of the therapeutic agent.
    Type: Application
    Filed: April 17, 2003
    Publication date: September 25, 2003
    Applicant: The Cleveland Clinic Foundation
    Inventor: Stanley L. Hazen